乳児におけるコンジュガドのヘモフィルス・インフルーエンス b型ワクチンの互換性
E L Anderson1, M D Decker, J A Englund
1Department of Medicine, Saint Louis (Mo) University School of Medicine.
JAMA
|March 15, 1995
まとめ
Haemophilus influenzae type b (Hib) の連続的なワクチン組み合わせは安全かつ有効でした. PRP-OMPとHbOCワクチンの連続投与は,乳児における単一製品レジメントと比較して,比較可能なまたは優れた免疫原性を示しました.
科学分野:
- 小児感染症は,小児の感染症です.
- ワクチン学 ワクチン学
- 免疫学 免疫学とは
背景:
- Haemophilus influenzae type b (Hib) の結合ワクチン接種は,侵入性Hib疾患の予防に極めて重要です.
- PRP-OMPとHbOCという2つの主要な結合ワクチンがあり,異なるキャリアタンパク質を使用しています.
- これらのワクチンのシリアル組み合わせの評価は,幼児免疫スケジュールを最適化するために重要です.
研究 の 目的:
- 2つのHib結合ワクチン:PRP-OMPとHbOC.の連続投与による安全性と免疫原性を評価する.
- シリアル・コンビネーションの免疫原性を単一製品療法と比較する.
- 15ヶ月後に非結合PRPのプライミング効果を評価する.
主な方法:
- 497人の健康な2ヶ月の乳児を対象としたランダム化,ダブルブラインド臨床試験です.
- PRP-OMPとHbOCのシリアル組み合わせを含む5つの異なるHibワクチン接種が実施されました.
- 抗体濃度は,プライマリシリーズとブースター投与後に測定され,安全性が監視されました.
主要な成果:
- 第2回および第3回ワクチン接種後,およびブースター投与後のグループ間で,抗体濃度の幾何学的平均の有意な違いが観察されました.
- PRP-OMPとHbOCの連続組み合わせにより,抗体濃度が単一製品グループと同等またはそれ以上を達成しました.
- 異なるワクチン接種群の間では,副作用の有意な差異は認められなかった.
結論:
- Hib結合ワクチン (PRP-OMPとHbOC) の連続投与は安全である.
- これらのシリアル組み合わせは,少なくとも単一のワクチン製品を使用するのと同じくらい免疫性があります.
- この発見は,乳幼児の予防接種スケジュールにおけるシリアル組み合わせの使用の柔軟性を支持しています.
関連する概念動画
Vaccinations
Overview
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Influenza
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Bacterial Meningitis I: Introduction
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...


